CoChat

Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes

Waldrop, Megan A., Karingada, Cassandra, Storey, Mike A., Powers, Brenna, Iammarino, Megan A., Miller, Natalie F., Alfano, Lindsay N., Noritz, Garey, Rossman, Ian, Ginsberg, Matthew, Mosher, Kathryn A., Broomall, Eileen, Goldstein, Jessica, Bass, Nancy, Lowes, Linda P., Tsao, Chang-Yong, Mendell, Jerry R., Connolly, Anne M. · 2020 · Pediatrics
Cited by 130

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: Historically, autosomal recessive 5q-linked spinal muscular atrophy (SMA) has been the leading inherited cause of infant death. SMA is caused by the absence of the SMN1 gene, and SMN1 gene replacement therapy, onasemnogene abeparvovec-xioi, was Food and Drug Administration approved in May 2019. Approval included all children with SMA age <2 years without end-stage weakness. However, gene transfer with onasemnogene abeparvovec-xioi has been only studied in children age ≤8 months. METHODS: In this article, we report key safety and early outcome data from the first 21 children (age 1–23 months) treated in the state of Ohio. RESULTS: In children ≤6 months, gene transfer was well tolerated. In this young group, serum transaminase (aspartate aminotransferase and alanine aminotransferase) elevations were modest and not associated with γ glutamyl transpeptidase elevations. Initial prednisolone administration matched that given in the clinical trials. In older children, elevations in aspartate aminotransferase, alanine aminotransferase and γ glutamyl transpeptidase were more common and required a higher dose of prednisolone, but all were without clinical symptoms. Nineteen of 21 (90%) children experienced an asymptomatic drop in platelets in the first week after treatment that recovered without intervention. Of the 19 children with repeated outcome assessments, 11% (n = 2) experienced stabilization and 89% (n = 17) experienced improvement in motor function. CONCLUSIONS: In this population, with thorough screening and careful post–gene transfer management, replacement therapy with onasemnogene abeparvovec-xioi is safe and shows promise for early efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1542/peds.2020-0729

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 6 references

Cited by

See all 130

Metadata

Authors
Waldrop, M. A., Karingada, C., Storey, M. A., Powers, B., Iammarino, M. A., Miller, N. F., Alfano, L. N., Noritz, G., Rossman, I., Ginsberg, M., Mosher, K. A., Broomall, E., Goldstein, J., Bass, N., Lowes, L. P., Tsao, C.-Y., Mendell, J. R., & Connolly, A. M.
Venue
Pediatrics
Published
2020-09-01
Volume
146
Issue
3
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
OpenAlex
W3080552198
Cited by
130
References
6
FWCI
9.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. https://app.cochat.ai/papers/10.1542/peds.2020-0729
The paper
Waldrop, M. A., Karingada, C., Storey, M. A., Powers, B., Iammarino, M. A., Miller, N. F., Alfano, L. N., Noritz, G., Rossman, I., Ginsberg, M., Mosher, K. A., Broomall, E., Goldstein, J., Bass, N., Lowes, L. P., Tsao, C.-Y., Mendell, J. R., & Connolly, A. M. (2020). Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. Pediatrics. https://doi.org/10.1542/peds.2020-0729

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.